Evidence map›Paper›PMID 26433956›Full record

ArticleEuropean radiology2016

Monitoring Crohn's disease during anti-TNF-α therapy: validation of the magnetic resonance enterography global score (MEGS) against a combined clinical reference standard.

Davide Prezzi, Gauraang Bhatnagar, Roser Vega, Jesica Makanyanga, Steve Halligan, Stuart Andrew Taylor

Abstract readValidation Study
PubMed Publisher
In one paragraph

Article in European radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. UEG Week 2019 Poster Presentations.United European gastroenterology journal · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Davide PrezziCentre for Medical Imaging, University College London, 3rd floor east, 250 Euston Rd, London, NW1 2PG, UK.
Gauraang BhatnagarCentre for Medical Imaging, University College London, 3rd floor east, 250 Euston Rd, London, NW1 2PG, UK.
Roser VegaGastrointestinal Services, University College Hospital, Ground floor west, 250 Euston Road, London, NW1 2PG, UK.
Jesica MakanyangaCentre for Medical Imaging, University College London, 3rd floor east, 250 Euston Rd, London, NW1 2PG, UK.
Steve HalliganCentre for Medical Imaging, University College London, 3rd floor east, 250 Euston Rd, London, NW1 2PG, UK.
Stuart Andrew TaylorCentre for Medical Imaging, University College London, 3rd floor east, 250 Euston Rd, London, NW1 2PG, UK. stuart.taylor1@nhs.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess the ability of magnetic resonance enterography global score (MEGS) to characterise Crohn's disease (CD) response to anti-TNF-α therapy.

methodsThirty-six CD patients (median age 26 years, 20 males) commencing anti-TNF-α therapy with concomitant baseline MRI enterography (MRE) were identified retrospectively. Patients' clinical course was followed and correlated with subsequent MREs. Scan order was randomised and MEGS (a global activity score) was applied by two blinded radiologists. A physician's global assessment of the disease activity (remission, mild, moderate or severe) at the time of MRE was assigned. The cohort was divided into clinical responders and non-responders and MEGS compared according to activity status and treatment response. Interobserver agreement was assessed.

resultsMedian MEGS decreased significantly between baseline and first follow-up in responders (28 versus 6, P < 0.001) but was unchanged in non-responders (26 versus 18, P = 0.28). The median MEGS was significantly lower in clinical remission (9) than in moderate (14) or severe (29) activity (P < 0.001). MEGS correlated significantly with clinical activity (r = 0.53; P < 0.001). Interobserver Bland-Altman limits of agreement (BA LoA) were -19.7 to 18.5.

conclusionsMEGS decreases significantly in clinical responders to anti-TNF-α therapy but not in non-responders, demonstrates good interobserver agreement and moderate correlation with clinical disease activity. KEY POINTS: • MRI scores of Crohn's activity are used increasingly in clinical practice and therapeutic trials. • Such scores have been advocated as biomarkers of therapeutic response. • MEGS reflects clinical response to anti-TNF-α therapy and the clinical classification of disease activity. • MEGS demonstrates good interobserver agreement.

Indexed as

AdolescentAdultBiomarkersCrohn DiseaseFemaleGastrointestinal TractHumansMagnetic Resonance ImagingMaleMiddle AgedReproducibility of ResultsRetrospective StudiesTreatment OutcomeTumor Necrosis Factor-alphaYoung AdultBiomarkersTumor Necrosis Factor-alphaBiological therapyCrohn’s diseaseEnterographyMagnetic resonance imagingTherapeutic monitoring

Identifiers

PMID26433956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.